Drug Type Gene therapy, Hematopoietic stem cell therapy |
Synonyms autologous NY-ESO-1 CD4-TCR CD34+ HSC(Roswell Park Cancer Institute) |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), Cell replacements |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Fallopian Tube Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Platinum-Resistant Ovarian Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Platinum-Sensitive Fallopian Tube Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Platinum-Sensitive Primary Peritoneal Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Recurrent ovarian cancer | Phase 1 | US | 08 Mar 2019 | |
Recurrent Primary Peritoneal Carcinoma | Phase 1 | US | 08 Mar 2019 | |
Refractory Ovarian Carcinoma | Phase 1 | US | 08 Mar 2019 |